Results 61 to 70 of about 2,835 (182)

Effects of hypnotic bromovalerylurea on microglial BV2 cells

Journal of Pharmacological Sciences, 2017
An old sedative and hypnotic bromovalerylurea (BU) has anti-inflammatory effects. BU suppressed nitric oxide (NO) release and proinflammatory cytokine expression by lipopolysaccharide (LPS)-treated BV2 cells, a murine microglial cell line.
Shun Kawasaki, Naoki Abe, Fumito Ohtake, Afsana Islam, Mohammed Emamussalehin Choudhury, Ryo Utsunomiya, Satoshi Kikuchi, Tasuku Nishihara, Jun Kuwabara, Hajime Yano, Yuji Watanabe, Mayuki Aibiki, Toshihiro Yorozuya, Junya Tanaka   +13 more
doaj   +1 more source

Management of Refractory and Difficult‐To‐Treat Inflammatory Bowel Disease: An Expert Opinion Review

JCC Plus, Volume 1, Issue 5, September 2026.
This expert opinion offers a practical framework for refractory and difficult‐to‐treat IBD: confirm inflammation objectively, distinguish pharmacologic from structural and functional disease, and then escalate. Across ten clinical questions, the evidence is often limited to case series, and the resulting statements are identified as expert opinion ...
Filiz Akyuz, Oguz Kagan Bakkaloglu, Nalan Gulsen Unal, Ismail Hakki Kalkan, Mehmet Arhan, Ibrahim Hatemi, Taylan Kav, Murat Toruner, Hale Akpinar, Ahmet Tezel, Aykut Ferhat Celik   +10 more
wiley   +1 more source

HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis

JEADV Clinical Practice, Volume 5, Issue 3, Page 974-978, September 2026.
ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal, Emily Moon, Georgios Kallikas   +2 more
wiley   +1 more source

Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial

, 2021
OBJECTIVES: To assess the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active AS in the TORTUGA trial. METHODS: In the TORTUGA trial, patients with AS received filgotinib
Østergaard, Mikkel, Baraliakos, Xenofon, Maksymowych, Walter P., Maksymowych, Walter P, Hendrikx, Thijs, Besuyen, Robin, Landew, Robert, Barchuk, William, Landewé, Robert, Gilles, Leen, Liu, Ke   +10 more
core   +1 more source

Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances

MedComm, Volume 7, Issue 9, September 2026.
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a rising, multifactorial chronic disorder driven by dysregulated mucosal immunity in genetically susceptible individuals and influenced by environmental and microbial factors.
Andrea Papait, Anna Cargnoni, Franco Scaldaferri, Loris Lopetuso, Antonietta Rosa Silini, Ornella Parolini   +5 more
wiley   +1 more source

Infection risk in rheumatoid arthritis patients treated with biologic and targeted therapies

Rheumatology &Autoimmunity, Volume 6, Issue 3, Page 149-159, September 2026.
In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of RA patients, including the characteristics of the susceptible patients and their concomitant therapy. We aim to provide a benefit‐risk analysis for clinical decision, and vital indications for the prevention of highly correlated ...
Lujing Wang, Jieshi Lin, Jie Qian
wiley   +1 more source

Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry

Objectives: The aim of this study was to evaluate the effectiveness and safety profile of filgotinib, a JAK1 preferential inhibitor, in rheumatoid arthritis (RA) patients included in Italian GISEA (Group for the Study of Early Arthritis) registry ...
Fornaro, Marco, De Stefano, Ludovico, Iannone, Florenzo, Bazzani, Chiara, Cauli, Alberto, Chimenti, Maria Sole, Atzeni, Fabiola, Ferraccioli, Gianfranco, Perniola, Simone, Congia, Mattia, Conti, Fabrizio, Lapadula, Giovanni, Bugatti, Serena, Caporali, Roberto, Biggioggero, Martina   +14 more
core   +2 more sources

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, Volume 81, Issue 9, Page 3039-3070, September 2026.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
Franziska Roth‐Walter, Ian M. Adcock, Cristina Benito‐Villalvilla, Rodolfo Bianchini, Leif Bjermer, Gaetano Caramori, Luigi Cari, Kian Fan Chung, Zuzana Diamant, Ibon Eguiluz‐Gracia, Edward F. Knol, Milos Jesenak, Francesca Levi‐Schaffer, Giuseppe Nocentini, Liam O'Mahony, Oscar Palomares, Frank Redegeld, Milena Sokolowska, Betty Van Esch, Marco Zurlo, Cristiana Stellato   +20 more
wiley   +1 more source

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 6, Page 729-747, September 2026.
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins, Srinivas Kamath, Rachel H. Davis, Samuel P. Costello, Robert V. Bryant, Alice S. Day, Paul Joyce   +6 more
wiley   +1 more source

A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost‐Effective: Results of the Multicentre IBD Value Study

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 3, Page 313-325, August 2026.
This study provides real‐world evidence that implementing an advanced therapy care pathway for patients with IBD leads to significant healthcare cost savings without compromising quality of life. These findings support broader implementation of care pathways in the management of patients with chronic conditions to optimise care delivery and resource ...
Elyke H. Visser, Martijn. A. Oude Voshaar, Reinier C. A. van Linschoten, Alexander G. L. Bodelier, Claire Fitzpatrick, Vincent de Jonge, Hestia Vermeulen, K. Evelyne Verweij, Sanne van der Wiel, Daniëlle van der Horst, C. Janneke van der Woude, R. L. West, D. van Noord   +12 more
wiley   +1 more source